13F Portfolios

INVESTOR AB: BIOMARIN PHARMACEUTICALS (BMRN): Quarterly 13F Position History

As of Q1 2026, INVESTOR AB reported 3,700 shares of BIOMARIN PHARMACEUTICALS (BMRN), worth $209.0K and representing 0.0% of its 13F equity book. The position first appeared in Q1 2025 and has been disclosed across 5 13F-HR filings in Pactolio's tracked window.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 5 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 3,700 0 $209.0K 0.0% $56.5
Q4 2025 3,700 0 $219.9K 0.0% $59.4
Q3 2025 3,700 0 $200.4K 0.0% $54.2
Q2 2025 3,700 0 $203.4K 0.0% $55.0
Q1 2025 3,700 $261.6K 0.0% $70.7

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did INVESTOR AB first disclose a BMRN position in 13F-HR filings?

INVESTOR AB first reported BIOMARIN PHARMACEUTICALS (BMRN) on its 13F-HR filing for the period ending 2025-03-31 (Q1 2025). The position has appeared on 5 reported quarters within Pactolio's tracked window.

What was INVESTOR AB's most recent quarter-over-quarter share-count change in BMRN?

INVESTOR AB held the same 3,700 shares of BMRN between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.

Does the implied price-per-share represent INVESTOR AB's cost basis in BMRN?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.